Welcome to our dedicated page for Cytokinetics SEC filings (Ticker: CYTK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cytokinetics, Incorporated filings document a specialty cardiovascular biopharmaceutical company with common stock listed on the Nasdaq Global Select Market. Its 8-K reports cover financial results, corporate presentations, MYQORZO® regulatory approvals, clinical and regulatory disclosures, and material capital-structure events such as underwriting agreements for common stock offerings.
Proxy materials describe board elections, executive compensation, auditor ratification and equity plan amendments, including matters tied to the company’s employee stock purchase plan. Other filings address governance changes, risk disclosures, registered securities, exhibits and Inline XBRL cover-page data associated with Cytokinetics’ public-company reporting obligations.
EVP R&D Dr. Fady I. Malik reported one option exercise and a matching open-market sale on 22 Jul 2025. He exercised 2,000 non-qualified options at $10.60, receiving 2,000 CYTK shares (Code M), then sold the same 2,000 shares at $37.47 (Code S). Net share count declined slightly from 142,610 to 140,610 shares, all held directly. Malik still holds 13,105 unexercised options with a $10.60 strike expiring 28 Feb 2027.
The trade represents roughly 1.4% of his direct equity position and appears to be a routine liquidity event following option exercise rather than a wholesale reduction. No other executives are involved and there are no disclosures affecting company fundamentals.